Gilead Sciences Inc. (NASDAQ: GILD) is an international stock currently in the Cadence portfolio and was the first offshore listed position in the fund, initiated in mid-2014.
In summary, Gilead is a large US biotech stock specialising in antiviral drugs to treat patients suffering from HIV, hepatitis C, influenza and other medical conditions.
In 2014 it generated approximately US$25bn in revenue and currently has a market capitalisation of US$180 billion (this is larger than any company listed on the ASX). As the world’s leading anti-viral company, Gilead holds strong market positions in some very lucrative markets.
Click here to read the full article.
